Evozyne uses advanced computational and machine-learning methods in its evolution-based engineering process to create synthetic proteins with precision and efficiency. In partnership with Takeda, Evozyne will create novel protein sequences for gene therapies. At completion, Takeda will have the option to obtain an exclusive license to develop and commercialize the novel protein sequences as part of its gene therapy program.

Under the agreement, Evozyne is eligible to receive an upfront payment of an undisclosed amount and additional research, development, and regulatory milestone payments, as well as royalties on sales of any commercial products resulting from the collaboration.

Elektrofi, Takeda partner to advance plasma protein therapeutics
Biotechnology firm Elektrofi and Takeda Pharmaceuticals have partnered to advance high-concentration, low-viscosity protein therapeutics.

Takeda opens new cell therapy manufacturing facility
Takeda Pharmaceuticals said it has opened a new 24,000-sq-ft research and development (R&D) cell therapy manufacturing facility at its R&D headquarters...

Takeda, Twist partner on biologics discovery
Twist Bioscience and Takeda Pharmaceutical have formed a partnership for access to Twist's proprietary phage display libraries for the discovery of antibodies...

Carmine, Takeda use extracellular vesicles for rare disease gene therapies
Carmine Therapeutics has signed a research collaboration agreement with Takeda Pharmaceutical to develop gene therapies for rare diseases.